Get the Stockscreener App
0.7556
1.24%
-0.0095
After Hours:
.73
-0.0256
-3.39%
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech Announces Leadership Change Amid CEO Departure - TipRanks
Oncolytics Biotech (TSE:ONC) Shares Up 2.9%Here's Why - MarketBeat
Oncolytics Biotech (TSE:ONC) Sets New 1-Year LowHere's Why - MarketBeat
What is HC Wainwright's Estimate for ONCY FY2024 Earnings? - MarketBeat
Oncolytics Biotech Announces Leadership Change Amid CEO’s Health Concerns - TipRanks
ONCYOncolytics Biotech, Inc. Common Shares Latest Stock News & Market Updates - StockTitan
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence - PR Newswire
Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX - Simply Wall St
Pre-Op Immunotherapy May Help Treat Aggressive Breast Cancers - 69News WFMZ-TV
HC Wainwright Reaffirms Buy Rating for Oncolytics Biotech (NASDAQ:ONCY) - MarketBeat
Equities Analysts Offer Predictions for ONCY FY2024 Earnings - Defense World
Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? - MSN
H.C. Wainwright maintains $5 target on Oncolytics Biotech stock - MSN
Can you now get a good deal on Oncolytics Biotech, Inc’s shares? - US Post News
FY2029 Earnings Forecast for ONCY Issued By HC Wainwright - Defense World
FY2029 Earnings Forecast for TSE:ONC Issued By HC Wainwright - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
Financial Metrics Exploration: Understanding Oncolytics Biotech, Inc (ONCY) Through Ratios - The Dwinnex
Brokers Offer Predictions for ONCY FY2029 Earnings - MarketBeat
FY2029 Earnings Estimate for TSE:ONC Issued By HC Wainwright - MarketBeat
H.C. Wainwright maintains $5 target on Oncolytics Biotech stock By Investing.com - Investing.com Australia
Oncolytics Biotech’s Pelareorep Advances: Promising Phase 2 Results and Regulatory Momentum Affirm Buy Rating - TipRanks
Oncolytics Biotech (TSE:ONC) Sets New 52-Week LowHere's What Happened - MarketBeat
JA Canada, Coke Canada Bottling and The Coca-Cola Company Partner to Advance Youth Employability in Canada - The Globe and Mail
Transformational Acquisition Has Shares Of This Miner Surging Higher - The Globe and Mail
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium - The Malaysian Reserve
Special Economic Zone License Sends Shares Higher - The Globe and Mail
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - The Globe and Mail
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastroin - GuruFocus.com
Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers At 2025 Asco GI Symposium - Marketscreener.com
Oncology Experts Predict 2025 Will Be a Year of Breakthroughs in Treatment and Prevention - Baystreet.ca
USA News Group: Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - finanznachrichten.de
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus - GlobeNewswire
Oncolytics Biotech Presents Promising Cancer Treatment Data - TipRanks
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial - MSN
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
Oncolytics Biotech (TSE:ONC) Shares Down 3.4%What's Next? - MarketBeat
Oncolytics Biotech Inc. Announces Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Marketscreener.com
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Stocks In Play: Oncolytics Biotech Inc - Barchart
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Lelezard
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Barchart
Oncolytics Biotech (TSE:ONC) Trading Down 3.4%Time to Sell? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Regulatory Approval Clears Path for Oncolytics Biotech® to Advan - GuruFocus.com
Oncolytics Biotech Advances Pancreatic Cancer Treatment with Regulatory Approval - TipRanks
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):